

| OMB APPROVAL | |
|--|-----------|
| OMB Number: | 3235-0104 |
| Estimated average burden hours per response: | 0.5 |

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| | | | |
|---|---|---|--|
| 1. Name and Address of Reporting Person* <u>Etherington Robert Dee</u> <hr/> (Last) (First) (Middle) 6550 SOUTH MILLROCK DRIVE SUITE G50 <hr/> (Street) SALT LAKE CITY UT 84121 <hr/> (City) (State) (Zip) | 2. Date of Event Requiring Statement (Month/Day/Year) 12/30/2020 | 3. Issuer Name and Ticker or Trading Symbol <u>Clene Inc. [CLNN]</u> | |
| | | 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Chief Executive Officer</u> | 5. If Amendment, Date of Original Filed (Month/Day/Year) 01/04/2021 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person |

Table I - Non-Derivative Securities Beneficially Owned

| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
|---------------------------------|---|--|---|
|---------------------------------|---|--|---|

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
|--|--|-----------------|---|----------------------------|--|--|---|
| | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | |
| Stock Options (Right to buy) | (2) | (2) | Common Stock | 428,674 | 0.53 ⁽¹⁾ | D | |
| Stock Options (Right to buy) | (3) | (3) | Common Stock | 1,092,777 | 0.15 ⁽¹⁾ | D | |

Explanation of Responses:

- This Form 3 amendment is being filed to correct an error in the original Form 3 filed on January 4, 2021 and subsequently amended on January 7, 2021 to reflect a correction in the exercise price that resulted from an internal calculation error.
- Awarded under the Clene Nanomedicine, Inc. 2014 Stock Plan on November 23, 2015 and currently exercisable. The options expire 10 years from the date of the grant.
- Awarded under the Clene Nanomedicine, Inc. 2014 Stock Plan on July 31, 2014 and currently exercisable. The options expire 10 years from the date of the grant.

Remarks:

/s/ Jerry Miraglia POA 04/13/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.